ImmunoGen, Inc. (IMGN)
| Market Cap | 3.95B |
| Revenue (ttm) | 189.56M |
| Net Income (ttm) | -182.03M |
| Shares Out | 248.94M |
| EPS (ttm) | -0.72 |
| PE Ratio | n/a |
| Forward PE | 91.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,639,959 |
| Open | 16.03 |
| Previous Close | 16.00 |
| Day's Range | 15.76 - 16.11 |
| 52-Week Range | 3.61 - 20.69 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+44.93%) |
| Earnings Date | Nov 3, 2023 |
About IMGN
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial fo... [Read more]
Financial Performance
In 2022, ImmunoGen's revenue was $108.78 million, an increase of 55.72% compared to the previous year's $69.86 million. Losses were -$222.93 million, 60.0% more than in 2021.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for IMGN stock is "Strong Buy." The 12-month stock price forecast is $23.0, which is an increase of 44.93% from the latest price.
News
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from two subset...
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer.
ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical
Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with Takeda Pharmaceutical Co. Ltd. TAK, +0.59% 4502, ...
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan.
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer.
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results.
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will p...
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates.
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will ho...
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. NASDAQ: IMGN is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver cancer-killin...
ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced updated data from an int...
Cancer drugmakers rise as industry meet fuels investor interest
Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago.
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference.
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its prev...
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting.
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. NASDAQ: IMGN shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for progre...
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underw...
ImmunoGen Announces Proposed Public Offering of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Proposed Public Offering of Common Stock.
Immunogen stock more than doubles on heavy volume after positive trial data ovarian cancer treatment
Shares of Immunogen Inc. IMGN blasted 121.2% higher on heavy volume toward a five-year high in premarket trading Wednesday, after the biopharmaceutical company revealed positive data from a late-stage...
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data f...
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the b...
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer.
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will ho...
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced it has entered into a t...